| Literature DB >> 36080283 |
Viktória L Balázs1, Rita Filep1, Fanni Répás1, Erika Kerekes2, Péter Szabó3, Béla Kocsis4, Andrea Böszörményi5, Judit Krisch6, Györgyi Horváth1.
Abstract
The biofilm formation of bacteria in different parts of the human body can influence the success of antibiotic therapy. Essential oils (EOs) and their components are becoming increasingly popular in point of view of medicinal applications, because of their antibacterial efficacy. The immortelle EO has been used traditionally as an expectorant; however, there are no studies summarizing its antibacterial effect against respiratory tract bacteria. Our aim was to investigate the antibacterial and biofilm inhibitory activity of immortelle (Helichrysum italicum) EO against respiratory tract pathogens such as Haemophilus influenzae, H. parainfluenzae, Pseudomonas aeruginosa and Streptococcus pneumoniae. In order to prove the antibacterial effect of the immortelle EO, broth microdilution and biofilm inhibition tests, and membrane damage assay were investigated. Scanning electron microscopy was used to identify the structural modifications in bacterial cells. Our results showed that immortelle EO has antibacterial and anti-biofilm effects against respiratory tract bacteria used in this study. H. parainfluenzae was the most sensitive to each treatment, however, P. aeruginosa was the most resistant bacteria. In conclusion, the studied EO may have a role in the treatment of respiratory tract infections due to their antibacterial and anti-biofilm activity.Entities:
Keywords: antibacterial activity; biofilm inhibition; essential oil; immortelle; respiratory tract
Mesh:
Substances:
Year: 2022 PMID: 36080283 PMCID: PMC9457731 DOI: 10.3390/molecules27175518
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Percentage composition of immortelle oil. Values are averages of three parallel measurements.
| Compounds | KI | Percentage of Compounds (%) |
|---|---|---|
| 939 | 6.7 | |
| Cymene | 1025 | 1.1 |
| Limonene | 1029 | 2.2 |
| 1,8-cineole | 1031 | 0.7 |
| Linalool | 1097 | 2.2 |
| Pentyl-methyl-butanoate | 1060 | 2.3 |
| Terpinene-4-ol | 1177 | 1.1 |
| α-Terpineol | 1189 | 0.8 |
| Nerol | 1230 | 0.9 |
| Neral | 1235 | 0.5 |
| Neryl acetate | 1362 | 21.2 |
| Cyclosativene | 1371 | 0.7 |
| 1377 | 4.5 | |
| 1401 | 8.8 | |
| 1413 | 2.1 | |
| 1419 | 0.5 | |
| α- | 1435 | 4.2 |
| Geranyl propionate | 1476 | 4.0 |
| Citronellyl isobutyrate | 1482 | 1.8 |
| 1464 | 0.5 | |
| 1484 | 3.2 | |
| 1481 | 15.9 | |
| 1490 | 7.2 | |
| α-Selinene | 1498 | 1.7 |
| 1514 | 0.2 | |
| 1523 | 0.2 | |
| Caryophyllene oxide | 1583 | 4.2 |
| Globulol | 1585 | 0.7 |
| Sum | 100 |
KI: Kovats Index [41].
The minimum inhibitory concentrations (MIC, mg/mL in case of essential oil; MIC: µg/mL in case of antibiotics) of antibiotics and immortelle essential oil on respiratory tract bacteria.
|
|
|
|
| |
|---|---|---|---|---|
| immortelle EO | 0.625 | 0.375 | 0.312 | 0.312 |
| gentamicin | 2 | - | - | - |
| imipenem | - | 0.4 | - | - |
| amikacin | - | - | 0.8 | 0.8 |
Figure 1Biofilm degradation activity of immortelle EO against respiratory tract bacteria. The anti-biofilm activity was calculated and demonstrated in terms of inhibitory rate according to the equation: Inhibitory rate = (1 − S/C) × 100% (C and S were defined as the average absorbance of control and sample groups, respectively). Different lowercase letters (a, b, c) above boxes indicate significant differences at p ≤ 0.05.
The effect of immortelle EO at different concentrations on the release of cellular material, absorbing at 260 nm.
| Concentrations |
|
|
|
|
|---|---|---|---|---|
| A260 (%) | ||||
| MIC/4 | 0 | 0 | 0 | 0 |
| MIC/2 | 0 | 0 | 0 | 0 |
| MIC | 32.1 ± 1.2 | 36.3 ± 1.9 | 40.8 ± 2.9 | 46.9 ± 0.8 |
| MIC × 2 | 79.0 ± 1.5 | 83.7 ± 2.2 | 90.2 ± 2.4 | 96.1 ± 2.1 |
| MIC × 4 | 100 | 100 | 100 | 100 |
Data are the release values presented in percentage vs. total ± SD (n = 3). The degree of bacteriolysis was expressed in percentage compared to the MIC × 4 concentration.
The effect of immortelle EO on the release of cellular material, absorbing at 260 nm, from respiratory tract pathogens.
|
|
|
|
| |
|---|---|---|---|---|
| Time (min) | A260 (%) | |||
| 0 | 0 | 0 | 0 | 0 |
| 10 | 0 | 0 | 0 | 0 |
| 20 | 48.2 ± 2.8 | 52.1 ± 1.2 | 63.2 ± 1.9 | 69.8 ± 2.0 |
| 40 | 50.2 ± 0.8 | 55.3 ± 2.5 | 69.2 ± 2.1 | 70.7 ± 3.0 |
| 60 | 79.1 ± 1.5 | 83.7 ± 2.2 | 90.2 ± 2.4 | 96.1 ± 2.1 |
| 90 | 81.2 ± 2.8 | 89.8 ± 3.1 | 95.9 ± 0.9 | 98.6 ± 0.7 |
Data are the release values presented in percentage vs. total ± SD (n = 3).
Figure 2Scanning electron microscopic images of H. influenzae (A,C), H. parainfluenzae (B,D), P. aeruginosa (E,G) and S. pneumoniae (F,H) biofilms. (A,B,E,F): Control samples of bacterial strains: (A)—H. influenzae, (B)—H. parainfluenzae, (E)—P. aeruginosa, (F)—S. pneumoniae. (C,D,G,H): Treated bacterial biofilms by Tween40 emulsion of immortelle EO: (C)—H. influenzae, (D)—H. parainfluenzae, (G)—P. aeruginosa, (H)—S. pneumoniae. Immortelle EO was used in MIC/2 concentration.
Figure 3Micrograph—Scanning electron microscopic images of H. parainfluenzae and S. pneumoniae treated by immortelle EO. (A): Untreated control of H. parainfluenzae, (B): Untreated control of S. pneumoniae cells. (C): Treated sample of H. parainfluenzae, (D): Treated sample of S. pneumoniae. Immortelle EO was used in MIC × 2 concentration. The arrows show the malformed and burst cells.